



AFRL-HE-BR-TR-2007-0015

**TESTING THE VIABILITY OF STORED FROZEN
SERUM SAMPLES FROM THE AIR FORCE
HEALTH STUDY USING
HUMAN MULTI-ANALYTE PROFILES (MAP™)**

Marian Pavuk, PhD

SpecPro, Inc.

**HUMAN EFFECTIVENESS DIRECTORATE
DIRECTED ENERGY BIOEFFECTS DIVISION**

September 2006

**Approved for public release, distribution
is unlimited.**

**Air Force Research Laboratory
Human Effectiveness Directorate
Information Operations and
Special Program Division Brooks-
City-Base, TX 78235**

NOTICES

This report is published in the interest of scientific and technical information exchange and does not constitute approval or disapproval of its ideas or findings.

Using Government drawings, specifications, or other data included in this document for any purpose other than Government-related procurement does not in any way obligate the US Government. The fact that the Government formulated or supplied the drawings, specifications, or other data, does not license the holder or any other person or corporation, or convey any rights or permission to manufacture, use, or sell any patented invention that may relate to them.

The Office of Public Affairs has reviewed this paper and it is releasable to the National Technical Information Service, where it will be available to the general public, including foreign nationals.

The report has been reviewed and is approved for publication.

//SIGNED//

JULIE ROBINSON, GS-14, DAF
Principal Investigator, Air Force Health Study

//SIGNED//

GARRETT D. POLHAMUS, DR-IV, DAF
Chief, Directed Energy Bioeffects Division

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE (DD-MM-YYYY) 22-09-2006			2. REPORT TYPE Technical Report					
4. TITLE AND SUBTITLE Testing the viability of stored frozen serum samples from the Air Force Health Study using Human Multi-Analyte Profiles (MAP TM)						5a. CONTRACT NUMBER N/A		
						5b. GRANT NUMBER N/A		
						5c. PROGRAM ELEMENT NUMBER N/A		
6. AUTHOR(S) Marian Pavuk, PhD						5d. PROJECT NUMBER 2276		
						5e. TASK NUMBER YA		
						5f. WORK UNIT NUMBER 01		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) AFRL/HEDA 2655 Flight Nurse Road Brooks City-Base, Texas 7823-5137						8. PERFORMING ORGANIZATION REPORT NUMBER N/A		
SpecPro Inc 12500 San Pedro Ave., Suite 670 San Antonio, TX 78216								
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) Air Force Materiel Command Air Force Research Laboratory Human Effectiveness Directorate Information 2655 Flight Nurse Road Brooks City-Base, TX 78235						10. SPONSOR/MONITOR'S ACRONYM(S) AFRL/HEDA		
						11. SPONSOR/MONITOR'S REPORT NUMBER(S) AFRL-HE-BR-TR-2007-0015		
						12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release: distribution unlimited.		
13. SUPPLEMENTARY NOTES Cleared for public release PA 07-114: 05 Apr 07								
14. ABSTRACT We assessed whether the Air Force Health Study (AFHS) frozen samples were viable for use in future studies using the Rules Based Medicine (RBM) Multi-Analyte Profiles (MAP tm) technologies applied to assay specific biochemical parameters. We randomly chose five AFHS veterans who participated at the 1982, 1985, 1987, 1992, and 1997 physical examinations and had multiple serum samples stored. One sample per examination per participant was selected for a total of 25 serum samples analyzed by MAP. MAPs are high-density, quantitative immunoassays panels that allowed each serum specimen to be analyzed for 78 specific serum antigens, 43 autoimmune serologies and 56 infectious disease serologies for a total of 177 analytes in one complex analytical procedure using 100 µl of sera. Overall, 96% of analytes provided measurable results and 83% (147 of 177) of analytes showed complete results for all five veterans for all five examinations. There was no indication that older samples were less well preserved than more recent ones. Comparison of quantitative result of 16 analytes measured at both the AFHS examinations and by the RBM human MAP panel found good correlations and agreement between the assays in stored frozen serum samples. Biochemical integrity of the samples appears to be well preserved and sensitive immunoassay based analyses were successfully performed.								
15. SUBJECT TERMS Hypertension, Agent Orange, dioxin, TCDD, Vietnam veterans, herbicides, Air Force Health Study, MAP TM								
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT		18. NUMBER OF PAGES		19a. NAME OF RESPONSIBLE PERSON	
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified	SAR		17		Julie N. Robinson	
			19b. TELEPHONE NUMBER (include area code)					

This page intentionally left blank

Table of Contents

1. Introduction	page 1
2. Materials and methods	page 1
3. Results	page 3
4. Discussion	page 7
5. References	page 9
6. Abbreviations	page 10

LIST OF TABLES

Table 1.	Correlation coefficients for selected AFHS and RBM biochemical measurements.....	page 5
Table 2.	Medians and ranges for biochemical parameters measured in AFHS and RBM where non-comparable methodologies were used or different form of a parameter was measured.....	page 6

TABLE OF FIGURES

Figure 1a-f.	Comparison of selected biochemical parameters from AFHS and RBM analyses in 25 stored frozen serum samples (1982-1997)...	page 3
--------------	---	--------

1. INTRODUCTION

The Air Force Health Study (AFHS) is a 20-year prospective study of the health, mortality and reproductive outcomes of Ranch Hand veterans who participated in the aerial spraying of herbicides, including Agent Orange contaminated with 2,3,7,8-tetrachlorodibenzo-p-dioxin (dioxin), in Vietnam from 1962 to 1971. The comparison group consisted of Air Force veterans who flew transport missions in Southeast Asia but were not involved in spraying herbicides. Six comprehensive medical examinations were conducted between 1982 and 2002 collecting a wealth of data and biological samples. Over 80,000 biological specimens including serum, blood, adipose tissue and urine were collected and stored during the course of the study, with some specimens stored for over 24 years. The present study examines whether the stored serum samples are well preserved and could be used for further research using microsphere-based multiplexed immunoassays - Human Multi-Analyte Profiles (MAPTM) by Rules-Based Medicine (RBM) (Austin, TX). Although not our primary interest, some earlier studies have shown that multiplexed immunoassays can provide results comparable to standard laboratory methods measured in serum, plasma, culture supernatants, or dried blood spots (Pang et al., 2005; Liu et al., 2005; DuPont et al., 2005; Lukacs et al, 2005; Zhang et al., 2006). This is to our knowledge the first study to report on using multiplexed methods on samples of long-term (up to 24 years) stored frozen serum.

2. MATERIALS AND METHODS

The details of the AFHS study design and subject selection were published previously (Wolfe et al., 1990). The study included periodic comprehensive medical examinations and in-person interviews, conducted in 1982, 1985, 1987, 1992, 1997, and 2002. To be selected for the viability study each participant had to fulfill the following criteria: a) be fully compliant to all six physical examinations, b) have in storage multiple 10 ml frozen serum specimens collected at each of the first five physical examinations, c) not have a history of cancer, d) have at least one quantifiable dioxin measurement, and e) signed an informed consent form. From participants satisfying all five criteria (n=988), five AFHS veterans were randomly chosen. One 10ml serum sample per examination per participant was selected for a total of 25 serum samples. The samples were selected from the first five physical examinations (1982, 1985, 1987, 1992, and 1997). The selected specimens were packed in dry ice and shipped to the contracted laboratory. Laboratory personnel were blinded to personal identifying information, cohort participation or dioxin levels of the selected participants.

The Rules-Based Medicine's Human MAPTM was used to analyze stored frozen serum samples. MAPs are high-density, quantitative immunoassay panels that allow identification of biomarker patterns and may provide a comprehensive evaluation of protein expression patterns indicative of response to disease, drugs, or the environment. The technology performs up to 100 multiplexed, microsphere-based assays in a single reaction vessel by combining optical classification schemes, biochemical assays, flow cytometry and advanced digital signal processing hardware and software. Details of the procedures have been described elsewhere (Fulton et al., 1997; Gordon and Dade, 1997).

Briefly, multiplexing is accomplished by assigning each analyte-specific assay a microsphere set (n=100) encoded with a unique fluorescence signature. Each microsphere set is conjugated with capture antibodies that react with the target protein. After the assay is complete, the microspheres pass single file past two lasers. The red laser (635 nm) excites the encoded dyes to identify the analyte; the green laser (532 nm) excites a reporter dye to quantify the result. Each serum specimen was analyzed for 78 specific serum antigens, 43 autoimmune serologies and 56 infectious disease serologies for a total of 177 analytes in one complex analytical procedure. Serum requirement for these analyses was 100 µl.


We identified 16 analytes measured repeatedly in at least 2 examinations during the course of the first five AFHS physical examinations that are also included in the RBM Human MAP™ for comparison. Eight of the selected analytes had continuous measured levels with normal, laboratory set ranges. These quantitative assays included alpha-1 antitrypsin, C3 complement, creatine kinase, IgA, IgM, PSA, SGOT/AST, and TSH. Results for creatine kinase and SGOT/AST were not directly comparable as RBM MAP panels are non-enzymatic assays. A total PSA was measured in AFHS, free PSA in the RBM panel. Eight other analytes had a positive or negative finding in the AFHS data – these included hepatic panel (HepA Ab, HBs Ag, HBc Ag, HBs Ab, HC Ab, HD Ab), mitochondrial antibodies, and thyroidal microsomal antibodies.

3. RESULTS


Two of the five selected subjects were Ranch Hand veterans and three were the Comparisons. Their ages at the baseline examination in 1982 ranged from 43 to 50 years old, their body mass index (BMI) was between 25 and 28.5. They had background 2,3,7,8-tetrachloro-p-dibenzodioxin (TCDD, dioxin) levels ranging from 3.7 pg/g lipid to 9.3 pg/g lipid measured in 1987 (one veteran in 1992). Of the 177 analytes examined 170 (96%) provided measurable results using RBM's MAP™ technology. Seven analytes provided results not measurable on the standard curve. These analytes are usually present only in pathologic conditions or are considered as potential surrogates of diseases and may be present in very low amounts in serum of relatively healthy subjects (IL-1beta, IL-2, IL-4, IL-6, MMP-9 – inflammation, cancer; glutathion-S-transferase – liver disease; calcitonin – thyroid disease). One-hundred-forty-seven (83%) analytes provided complete results for all analytes in all analyzed samples across all five cycles. Results below standard curves appeared to be subject-related rather than examination cycle/storage time-related, and were not related to dioxin or participation in Ranch Hand or Comparison cohort. We did not observe higher numbers of results below the standard curve for earlier examinations than for more recent ones (66 in 1982 samples versus 67 in 1997 samples; results for 23 analytes with at least one result below the standard curve; data not shown).

Eight analytes with continuous measurements and eight analytes with positive and negative results were identified in AFHS data for comparison with the RBM data. Results for alpha 1 - antitrypsin, IgG, IgM, TSH, PSA, and C-3 Complement are presented in Figure 1a through Figure 1f; other results for these analytes and SGOT/AST and creatine kinase are also presented in Tables 1 and 2. Results for positive and negative findings of eight additional analytes are described in the text.


a) Alpha-1 Antitrypsin



b) Immunoglobulin A (IgA)



c) Immunoglobulin M (IgM)



d) Thyroid Stimulating Hormone (TSH)





Figure 1. Comparison of selected biochemical parameters from AFHS and RBM analyses in 25 stored frozen serum samples (1982-1997).

Figure 1. (Continued)

e) Prostate Specific Antigen (PSA)

f) Complement C3



In Figure 1a, normal ranges for Alpha-1 Antitrypsin were similar for both methods, 0.9-2.2 mg/ml for the AFHS and 1.1-2.7 mg/ml for the RBM MAP. Results for all veterans were within normal ranges. Veteran #5 had consistently lower levels across all measurement cycles but no clear pattern in other veterans' levels was observed. We refer to a clear or similar pattern in results when the same or similar rank and magnitude of measurements emerged in veterans' results from both AFHS and RBM analyses. Alpha-1 Antitrypsin was not measured in 1982 and 1985 in the AFHS but the analyses on stored samples were successful using the RBM panel. Medians and ranges were similar and coefficient correlation between the AFHS and RBM measurements was high ($r=0.66$, Table 1).

Table 1. Correlation coefficients for selected AFHS and RBM biochemical measurements.

Parameter	N	Median	Min-Max	Correlation Coefficient	p-value
Alpha 1-antitrypsin ^a					
AFHS	15	1.35	0.85-1.79	0.66	0.007
RBM	15	1.70	0.71-2.20		
IgA ^b					
AFHS	20	1.70	0.73-3.34	0.94	<0.001
RBM	20	1.66	0.74-3.70		
IgM ^c					
AFHS	20	0.63	0.30-5.75	0.65	0.002
RBM	20	0.64	0.21-5		
TSH					
AFHS	25	2.20	0.5-10.1	0.73	<0.001
RBM	25	2.00	0.63-9.3		
C3 Complement ^d					
AFHS	15	1.11	0.8-1.61	0.53	0.04
RBM	15	1.10	0.54-1.5		

- a. Alpha 1-antitrypsin for 1982 and 1985 examinations in AFHS not reported.
b. IgA not reported for 1982 AFHS examination.
c. IgM not reported for 1982 AFHS examination.
d. C3 complement for 1982 and 1985 examinations in AFHS not reported.

Normal ranges for IgA in the AFHS were 0.78-2.86 mg/ml in 1985 and 0.69-3.82 mg/ml for the 1987-1997 examinations (no measurements in 1982). Corresponding ranges in RBM analyses were 0.58 to 5.8 mg/ml. A very similar pattern in the results from both methods is shown in Figure 1b. Additionally, veteran #5 is clearly identified as having higher IgA levels than other veterans but still within normal ranges by both methods. Similar clear patterns emerged for IgM analyses as shown in Figure 1c. Veteran #4 being correctly identified having higher than normal range levels of IgM in the RBM panel corresponding to the AFHS results. In Figure 1d, results from RBM analyses found TSH levels in veteran #5 elevated above normal range in 1982, 1985, 1992, and 1997, similar to AFHS results, and borderline elevated in 1987.

The methods of measurements and normal ranges changed in AFHS over the first three examinations but overall patterns for TSH were similar in both methods. Medians and ranges for IgA, IgM, and TSH were very similar between AFHS and RBM measurements with high correlation coefficients ranging from 0.65 for IgM and 0.73 for TSH to 0.94 of IgA (all p-values <0.005; Table 1).

Normal ranges for C3 complement were 0.85-1.93 mg/ml in AFHS and 0.89-2.5 mg/ml in RBM analyses. All results fell within the normal ranges for both sets of measurements without a clear distinguishing pattern in veterans' levels. Medians and ranges for C3 complement were similar as measured by both methods, with correlation coefficient of 0.53 (p-value =0.04, Table 1).

A total PSA was measured in 1992 and 1997 in the AFHS and free PSA in the RBM panel (for all examinations), but the patterns in 1992 and 1997 were similar for both measurements and these two sets of measurements were highly correlated (r=0.92, Table 2). For SGOT/AST and creatine kinase we would not expect the results to agree as an enzymatic method was used to measure these enzymes in the AFHS data. Amount or weight measured immunologically was ascertained by the RBM panel but the analyses were performed on all samples successfully. Medians and ranges for both methods are presented in Table 2).

Table 2. Medians and ranges for biochemical parameters measured in AFHS and RBM where non-comparable methodologies were used or different form of a parameter was measured.

Parameter	N	Median	Min-Max	Correlation Coefficient	p-value
PSA ^a					
PSA Total - AFHS	10	1.60	0.70-2.60		
Free PSA -RBM	10	0.51	0.24-1.10	(0.92)	(0.0001)
Creatine Kinase					
AFHS	25	101	24-286		
RBM	24 ^b	0.22	0.05-0.74	-- ^d	--
SGOT/AST					
AFHS	25	32	17-61		
RBM	23 ^c	3.4	0.37-6.5	-- ^d	--

a. PSA for 1982, 1985, and 1987 in AFHS not reported.

b. One RBM measurement missing.

c. Two RBM measurements missing.

d. Enzymatic method used in AFHS analyses, not directly comparable to immunologically measured amount or weight used in RBM analyses; calculating correlation coefficient inappropriate.

For positive and negative findings, none of the five selected veterans had a presence of mitochondrial or thyroid microsomal antibodies detected in 1992 or 1997 in the AFHS data. RBM technology assays were able to run analyses in samples from those examination cycles and also for 1982-1987 examinations and similarly found no positive reaction. A presence of HepA antibodies was detected in two veterans at 1987 and 1992 examinations, and in three veterans at the 1997 examination in the AFHS data. RBM analyses did not detect the antibodies in the same veterans. The discrepancy in the results may have been due to a different HepA serotype used to prepare the MAP HepA assay or other methodological issues. There was one veteran with positive HBs antibodies detected in 1982 and through following examinations; this veteran was also positive for HBc Ab. The RBM analysis correctly identified the veteran and confirmed these findings. No positive results were found for HC Ab or HD Ab by either assay.

4. DISCUSSION

In conclusion, 96% of all 177 analytes provided detectable results using high-density immunoassays performed by RBM's Human MAPTM technology using only 100 µl of sera. This technology appears to be a useful instrument in analysis of frozen serum samples that were stored for 9 to 24 years, especially in cases where a limited amount of sera is available and analyses of a large number of analytes are required. Biochemical integrity of the samples appears to be well preserved and sensitive immunoassay based analyses were successfully performed. The similarities in results between AFHS and RBM measurements, although not the primary goal of the study, showed good agreement and high correlations between the methods and further attest to the viability of the stored frozen serum samples. These results suggest that the stored AFHS samples represent a great source of phenotypic data that is well preserved and could be successfully used for future examination of protein pattern expressions related to environmental, disease or drug exposures.

ACKNOWLEDGEMENTS

We would like to thank Rules-Based Medicine for timely analysis of serum samples and their assistance in preparation of this manuscript. We also thank SAIC for facilitating the contract arrangements.

5. REFERENCES

- duPont NC, Wang K, Wadhwa PD, Culhane JF, Nelson EL. Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants. *J Reprod Immunol.* 2005; 66(2):175-91.
- Fulton RJ, McDade RL, Smith PL, Kienker LJ, Kettman JR Jr. Advanced multiplexed analysis with the FlowMetrix system. *Clin Chem.* 1997;43(9):1749-56.
- Gordon RF, McDade RL. Multiplexed quantification of human IgG, IgA, and IgM with the FlowMetrix system. *Clin Chem.* 1997;43(9):1799-801.
- Liu MY, Xydakis AM, Hoogeveen RC, Jones PH, Smith EO, Nelson KW, Ballantyne CM. Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system. *Clin Chem.* 2005;51(7):1102-9.
- Lukacs Z, Dietrich A, Ganschow R, Kohlschutter A, Kruithof R. Simultaneous determination of HIV antibodies, hepatitis C antibodies, and hepatitis B antigens in dried blood spots--a feasibility study using a multi-analyte immunoassay. *Clin Chem Lab Med.* 2005;43(2):141-5.
- Pang S., Smith J., Onley D., Reeve J., Walker M., Foy C. A comparability study of the emerging protein array platforms with established ELISA procedures. *J Immunol Methods.* 2005; 302(1-2):1-12.
- Wolfe W.H., Michalek J.E., Miner J.C., Rahe A.J., Silva J., Thomas W.F., Grubbs W.D., Lustik M.B., Karrison T.G., Roegner R.H. and Williams D.E. *JAMA.* 1990; 264:1824-31.
- Zhang H, Cheng X, Richter M, Greene MI. A sensitive and high-throughput assay to detect low-abundance proteins in serum. *Nat Med.* 2006;12(4):473-7.

6. ABBREVIATION

Abbreviation	Definition
BMI	Body Mass Index
ICD	International Classification of Diseases
kg	Kilogram
log	Logarithm
m	Meter
TCDD	2,3,7,8-tetrachlorodibenzo-p-dioxin

